(95) explored the effect of IL-6 on the sensitivity of HCC cells treated with sorafenib and its mechanism, and found that siIL-6 further promoted sorafenib to impede proliferation and induce apoptosis, suggesting that blocking IL-6 could be used as a potential therapeutic approach for sorafenib sensitivity of HCC cells. Here, IL6 is linked to hepatocellular carcinoma.